Heat’s HS-System – Safe and Novel Shotgun Immune Activation
Heat's HS-System enables the immune system to fight specific stealth targets such as cancer cells utilizing live, off-the-shelf genetically modified cells injected into a patient. Heat's HS-System reprograms tumor cells to "pump out" an important immuno-protein called gp96-Ig that robustly generates a potent immune response to cancer cells by mobilizing and activating killer T cells against multiple tumor antigens, thus stimulating the patient’s own IS to fight the cancer.
In contrast to other vaccine technologies, Heat’s novel shotgun approach enables the body to induce and maintain an immune response against multiple tumor proteins, thus unleashing a powerful multi-prong attack against the tumor. Clinical and pre-clinical results indicate that the HS-System generates a potent anti-tumor immune response that fights targeted tumors and keeps the body tumor-free even when re-challenged with the cancer. This novel live cell vaccine approach is applicable to a wide array of viral infections as well as cancer, HIV, HCV, Flu and other diseases. Heat’s approach is an off-the-shelf product that does not require invasive surgery or isolation of patient tissues.
The HS-System is currently being tested as both a therapeutic and prophylactic vaccine against HIV infection in non-human primates. This preclinical trial is the largest of its kind ever funded by the National Institutes of Health and is moving forward on the basis of unprecendented pre-clinical data.
Heat has initiated an aggressive development program to target its HS-System against a range of diseases. Heat is currently in Phase I clinical trials with its first HS-System based product, HS-L1, a treatment for Non-Small Cell Lung Cancer (NSCLC) and is working to initiate additional HS-System-based clinical trials for ovarian and pancreatic cancers.
